Biotech · Private company · San Ramon, CA, US
Artery Therapeutics, Inc.
Track this companyFree. Adds Artery Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards3
- Subcutaneous CS6253 9-Month Chronic Toxicology GLP Study in Cynomolgus Monkeys to assess Safety, Tolerability and PKFiscal year 2026 · $2.3MNIH RePORTER 1R44AG099463-01 · fetched Nov 12, 2026
- CS6253 Sequential Subcutaneous Pharmacokinetic Study followed by Phase 2A Placebo-Controlled Trial with Three Fixed Doses in APOE4 MCI and AD Patients to assess Safety, PK, and Biomarker EffectsFiscal year 2026 · $2.6MNIH RePORTER 1UG3AG098023-01 · fetched Nov 12, 2026
- Manufacturing of ABCA1 agonist small molecule peptide CS6253 to support chronic toxicology studies in Wistar rats and Cynomolgus monkeysFiscal year 2025 · $2.5MNIH RePORTER 1R44AG092185-01A1 · fetched Nov 12, 2026